An independent peptide reference — no sellers, every claim sourced

N-Acetyl Selank Amidate

Also known as NA-Selank-Amidate, NASA (Selank), Ac-Selank-NH2

Doubly modified Selank analogue sold by research-chemical vendors, with no published pharmacology of its own.

preclinical Neuro & cognition research chemical

At a glance

Category
Neuro & cognition
Status
research chemical
Route
intranasal or subcutaneous in vendor protocols; no route has been formally studied
Half-life
No published pharmacokinetic data exist for this compound in any species 1. Vendor claims of an extended duration relative to Selank have no traceable source.
Onset
Unknown; no controlled data on the time course of any effect
Molecular weight
Approximately 793 g/mol, calculated from the parent peptide (751.9 g/mol) plus acetylation and amidation. No independently determined value from a published characterisation of this compound was found.
Sequence
Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (the Selank sequence with an acetylated N-terminus and an amidated C-terminus)

Not registered as a medicine anywhere. The Russian registration held by Peptogen covers unmodified Selank as 0.15% nasal drops, not this compound. Acetylated and amidated Selank is a chemically distinct substance created and sold by peptide vendors, and a PubMed search for it returns no study of it at all 1. No EMA or FDA assessment.

Doping status: Not listed by name; as a non-approved substance it falls under the S0 residual category and is prohibited at all times

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

The modifications are the standard pair used to slow peptidase degradation: N-terminal acetylation removes the substrate for aminopeptidases and C-terminal amidation removes the substrate for carboxypeptidases. As chemistry this is unremarkable and generally effective at extending plasma survival. As pharmacology it is untested here.

Selank is a synthetic analogue of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro. Tuftsin's activity depends on a free N-terminal threonine and on the intact tetrapeptide being recognised by its target; acetylating that terminus is precisely the kind of change that can abolish tuftsin-like activity. Whether the modified peptide retains, loses or alters the parent's anxiolytic and GABAergic effects has never been measured. Every pharmacological statement made about this product is Selank's pharmacology, borrowed on the assumption that the modifications changed only stability.

Selank's own evidence base is limited and largely Russian-language (see that entry), so this is extrapolation from an already weak foundation.

What the research shows

A PubMed search for N-acetyl selank and selank amidate returns no study of this compound; the few hits concern unmodified Selank or unrelated N-acetyl chemistry 1. There is no published pharmacology, pharmacokinetics, efficacy or safety data for the modified peptide. There is nothing to weigh.

Research in humans

No published human studies of any kind. No pharmacokinetics, no safety study, no trial, no case series.

Animal and lab research

No published animal studies of the modified compound were found 1. Animal work cited in marketing material concerns unmodified Selank.

Caveats. No independent verification exists that commercially sold material has the claimed structure or purity; no demonstration that the modifications preserve tuftsin-like activity; no pharmacokinetic measurement of the claimed longer duration; no toxicology. Vendor certificates of analysis are self-issued and cannot be independently checked.

What it is used for

  • Sold and self-administered as a longer-acting alternative to Selank for anxiety and stress - claims taken from the parent compound 23, not demonstrated for this one 1
  • No research or clinical use is documented 1

Dosing

Route
intranasal or subcutaneous in vendor protocols
  • No credible dose exists. There is no dose-finding study, no pharmacokinetics and no dose-response data for this compound 1.
  • Vendor protocols scale down the Selank dose on the assumption that the modified peptide is more potent; that assumption has never been measured, so the resulting figures are arbitrary.
  • Deliberately left null rather than reproducing numbers that would lend a fabricated protocol an appearance of authority.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Intranasal spray or drops (user-reported)

user protocol — not validated

Source: Nootropic forum reports and vendor labelling

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Reported per-administration amountcommonly given as '1-2 sprays' or a few drops per nostril, once or twice daily
When expressed in microgramsroughly 100-300 mcg per administration is quoted, but the figure depends entirely on how the powder was reconstituted
Reported cyclecontinuous daily use, or courses of a few weeks; no consistent pattern

This is among the messiest sets of numbers in this reference. What circulates is not a dose but a volume - 'a spray', 'a couple of drops', 'one pump per nostril' - and the milligrams that volume delivers depend on how much powder the user dissolved in how much water and on the spray pump fitted to the bottle, none of which is standardised. The same threads carry the same nominal 'dose' expressed as sprays, as drops and as micrograms, and these do not convert into one another. Underneath all of it there is no pharmacology at all for this modified peptide 1: no dose-finding study, no pharmacokinetics, and no measurement of the higher potency vendors invoke to justify scaling the Selank dose down. The figures are borrowed from Selank and then adjusted by guesswork.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Vial sizes
5 mg, 10 mg, 20 mg (lyophilised powder, research chemical)
Solvent
bacteriostatic water (0.9% benzyl alcohol) in vendor practice
Storage
Supplier guidance: lyophilised powder at -20 °C protected from light, reconstituted material at 2-8 °C for a few weeks. No stability study of this compound has been published, so these figures are conventions rather than data.

Let the diluent run down the vial wall and swirl rather than shake. There is no published reference standard or analytical method for this compound, so identity and purity of grey-market material cannot be verified.

This is administered as nasal drops or spray, not by injection, so there is no syringe volume to work out.

Safety

Side effects

  • Not documented, because no safety study exists 1. An empty side effect list reflects absence of investigation, not demonstrated safety
  • By analogy with Selank: nasal irritation with intranasal use, and anecdotal drowsiness or blunted affect. Whether these transfer to the modified peptide is unknown

Do not use if

  • Pregnancy and breastfeeding - no data of any kind
  • Children and adolescents - no data
  • Hypersensitivity to the peptide or to benzyl alcohol in the diluent
  • No toxicology programme has ever been conducted on this compound 1, so no informed statement about who should avoid it is possible

Interactions

Not studied. No interaction data exist for this compound 1. Whether the parent compound's reported interaction with GABAergic and serotonergic systems applies here is unknown.

Sources